HealthCall:Brief Intervention to Reduce Non-injecting Drug Use in HIV Primary Care Clinics
This trial is active, not recruiting.
|Condition||mental and behavioral disorders due to multiple drug use and use of other psychoactive substances: harmful use|
|Treatments||healthcall and motivational interviewing, motivational interviewing (mi), hiv/aids health education|
|Phase||phase 1/phase 2|
|Sponsor||Research Foundation for Mental Hygiene, Inc.|
|Start date||June 2011|
|End date||August 2015|
|Trial size||390 participants|
|Trial identifier||NCT01312181, R01 DA024606|
Among HIV-infected individuals, non-injection drug use (NIDU) is associated with poor HIV medication adherence, greater HIV/AIDS risk behaviors, and increasing non-AIDS mortality. Thus reducing NIDU among HIV infected individuals is critical to their survival and to limiting the spread of HIV. We propose to study the efficacy of a technologically enhanced brief intervention (HealthCall) to reduce NIDU in HIV primary care patients that demands little from busy medical staff and is well accepted by patients. In a 3-arm randomized clinical trial will test the efficacy of (a) Motivational Interviewing (MI)+HealthCall; (b) MI-only; and (c) a control condition (advice + DVD HIV health education) in reducing NIDU.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Intervention model||parallel assignment|
The primary outcome variable is drug use, assessed at baseline and repeatedly during follow-up so that change can be analyzed.
time frame: Assessed at baseline, 30 and 60 days, 3,6 and 12 months
Male or female participants at least 18 years old.
- All research volunteers will be 18 and older and HIV positive. We will include participants whose primary drug is non-injection use of cocaine, opioids including heroin, or methamphetamines and current use in the past 30 days > 4 days. Participants will need to complete a medically supervised detoxification if such detoxification is required.
- Excluded are research volunteers for whom participation would not be clinically appropriate, who clearly could not participate. Psychotic, suicidal or homicidal patients require clinical management that is too intensive for this study, and we have no evidence that MI+HealthCall would be effective among injection drug users. Leaving New York precludes follow-up. Gross psychomotor/cognitive impairments that may hinder patients' HealthCall use. Hearing and severe vision impairments that preclude telephone use precludes randomization to MI+HealthCall.
|Official title||HealthCall: Brief Intervention to Reduce Drug Use in HIV Primary Care|
|Principal investigator||Efrat Aharonovich, PhD|
Call for more information